Topics
News
CME/CE
Editorial Advisory Board
Partnerships
Combination kills cancer
New York - Results from the largest-ever phase III trial in advanced metastatic melanoma, while preliminary, suggest dacarbazine (DTIC) plus an investigational antisense compound (oblimersen sodium, or Genasense) may significantly improve overall survival versus DTIC alone, according to Anna C. Pavlick, D.O.
Related Videos
Related Content
